FDA Approves Benlysta Autoinjector for Treatment of Children with Systemic Lupus Erythematosus

The U.S. Food & Drug Administration (FDA) has granted approval for a novel and less invasive belimumab (Benlysta®) treatment for children with systemic lupus erythematosus (SLE) ages five years and older to be administered by injection. This is the first and only treatment of its kind for children receiving standard therapy.

With provider approval, the pediatric autoinjector will enable children to be treated at-home by their caregiver, eliminating the need for children to travel to a hospital or clinic setting for treatment. The autoinjector will be available immediately.

Continue to follow the Lupus Foundation of America for updates on lupus drug developments. Learn more about Benlysta.